6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。
消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。此外，Tecvayli治疗多发性骨髓瘤的晚期研究显示无进展生存期和总生存期均有统计学显著改善；Tremfya获FDA批签标签扩展；皮下注射amivantamab在头颈癌中实现42%客观缓解率。多条管线数据集中释放积极信号，为公司研发实力和未来增长预期提供支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.